Pharmaceutical News
-
Gilead expands oncology and global health strategy through acquisition partnership and financing initiatives
Gilead Sciences has acquired Tubulis to enhance its oncology portfolio with advanced antibody-drug conjugate technologies, aiming to improve targeted cancer therapies. Additionally, Gilead partnered with the WHO to tackle visceral leishmaniasis, supporting treatment access. This dual strategy integrates oncology expansion with global health initiatives while strengthening financial capabilities for future growth. Read more
-
Lilly ASCO 2026 presentations highlight oncology pipeline advances across multiple tumor types
Eli Lilly and Company will showcase new oncology data at the 2026 ASCO Annual Meeting, emphasizing its late-stage pipeline in various cancers. Key presentations include findings on Jaypirca for B-cell malignancies and imlunestrant for advanced breast cancer. This aligns with Lilly’s focus on precision medicine and expanding treatment options for challenging tumors. Read more
-
Novartis Showcases Advances in Cancer Therapy at ASCO 2026
Novartis showcased new clinical data on radioligand therapy and cancer treatments at the 2026 ASCO and EHA meetings, focusing on prostate and breast cancer, as well as hematology. Key findings for Pluvicto, Kisqali, and Scemblix highlight advancements in targeted therapies, aiming for improved patient outcomes and commercial growth in oncology. Read more
-
FDA approves AstraZeneca’s Baxfendy as first aldosterone synthase inhibitor for adult hypertension management in US
AstraZeneca reported significant advancements in baxdrostat, an aldosterone synthase inhibitor, showing meaningful blood pressure reductions in Phase III trials for treatment-resistant hypertension. With ongoing trials for chronic kidney disease, baxdrostat targets a large unmet need and could potentially generate over $5 billion in peak annual sales if approved. Read more
-
AstraZeneca’s Enhertu Gains FDA Approval for Early Breast Cancer
AstraZeneca and Daiichi Sankyo’s Enhertu received U.S. FDA approval for neoadjuvant and adjuvant treatment of HER2-positive early breast cancer. The approvals were based on two Phase III trials, showcasing significant benefits in reducing disease recurrence. This expansion enhances Enhertu’s presence in HER2 therapy and offers patients new treatment options for improved outcomes. Read more
-
Novartis Pluvicto data shows 58% lower PSA progression risk in prostate cancer
Novartis reported that Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) reduced the risk of PSA progression by 58% in the Phase III PSMAaddition trial for metastatic hormone-sensitive prostate cancer. The findings suggest earlier use of this targeted radioligand therapy could enhance disease control and support Novartis’ growth in oncology with expanded patient eligibility. Read more
-
FDA approves LEO Pharma’s ANZUPGO Cream: Potential Pediatric Approval Insights
LEO Pharma’s sNDA for ANZUPGO® (delgocitinib) cream, aimed at treating moderate to severe chronic hand eczema in adolescents aged 12-17, has been accepted by the FDA. Supported by positive Phase III trial data, this potential approval could provide a much-needed treatment option for pediatric patients, enhancing LEO Pharma’s dermatology portfolio. Read more
-
UCB Joins Forces with Cancer Research UK for Cancer Therapies
UCB, Cancer Research UK, and Cancer Research Horizons have formed a strategic alliance to accelerate the development of cancer therapies. This collaboration builds on previous efforts and involves progressing UCB’s internal oncology projects into clinical trials, leveraging Cancer Research UK’s expertise. The goal is to enhance access to innovative treatments for challenging cancers. Read more
-
Biocon Pharma Receives Canada Approval for Micafungin Injection
Biocon Pharma Limited has gained Health Canada approval for Micafungin for Injection USP, available in 50 mg and 100 mg dosages. This antifungal medication targets serious fungal infections, enhancing Biocon’s anti-infectives portfolio and supporting its growth strategy in specialized injectables. The approval aims to improve access to essential treatments in hospital settings. Read more
-
GSK Partners with SBP Group for Bepirovirsen in China
GSK has partnered with China’s SBP Group to enhance the launch of bepirovirsen for chronic hepatitis B. SBP will utilize its network to promote patient access in a significant market. Bepirovirsen targets hepatitis B surface antigen, aiming for a functional cure following positive Phase III trials, aligning with GSK’s market strategies. Read more
-
FDA Approves Bizengri for NRG1 Fusion-Positive Cancer
The FDA has approved Bizengri (zenocutuzumab-zbco) for patients with NRG1 fusion-positive cholangiocarcinoma after prior therapy failure, marking the seventh approval under the National Priority Voucher Pilot Program. This decision, based on promising trial results, aims to expedite access to targeted treatments for rare cancers while fostering investment in precision oncology. Read more
-
Bristol Myers Squibb’s Sotyktu Approved for Active Psoriatic Arthritis in Europe
Bristol Myers Squibb’s Sotyktu (deucravacitinib) received European Commission approval for treating active psoriatic arthritis in adults. Based on Phase III trial results, Sotyktu showed significant efficacy in improving disease symptoms and has a favorable safety profile. This expansion enhances the company’s immunology portfolio and offers patients a new oral treatment option. Read more